Edmonton, Alberta--(Newsfile Corp. - December 1, 2023) - Pacylex Pharmaceuticals Inc. (Pacylex), a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies for the treatment of hematologic and solid tumor cancers, today announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex's lead product candidate, will be included in investor updates presented at upcoming conferences in December and January..

艾伯塔省埃德蒙顿-（Newsfile Corp.-December 12023）-Pacylex Pharmaceuticals Inc.（Pacylex），一家临床阶段制药公司，专注于开发一类新的靶向治疗方法，用于治疗血液学和实体肿瘤癌症，今天宣布其对zelenirstat的1期剂量递增安全性和耐受性研究结果，研究中的NMT抑制剂和Pacylex的主要产品候选人将被纳入即将在12月和1月举行的会议上介绍的投资者更新中。。

To view the full announcement, including downloadable images, bios, and more, click here.

要查看完整的公告，包括可下载的图像，生物学等，请单击此处。

Key Takeaways:

主要优点：

Phase 1 safety and tolerability of zelenirstat was acceptable and a recommended Phase 2 dose was established.

zelenirstat的1期安全性和耐受性是可接受的，并建立了推荐的2期剂量。

Zelenirstat unexpectedly prolonged progression free survival in solid tumor patients in Phase 1 at the recommended Phase 2 dose.

Zelenirstat出乎意料地延长了推荐的2期剂量的1期实体瘤患者的无进展生存期。

Pacylex will report Phase 1 safety results and potential efficacy signals at upcoming life science investment conferences in December 2023 and January 2024.

Pacylex将在2023年12月和2024年1月即将举行的生命科学投资会议上报告第一阶段安全性结果和潜在疗效信号。

Click image above to view full announcement.

点击上面的图片查看完整的公告。

About Pacylex Pharmaceuticals

关于Pacylex制药公司

Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with orally bioavailable NMT inhibitors. Zelenirstat is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment.

Pacylex是一家临床阶段制药公司，总部设在加拿大艾伯塔省埃德蒙顿，用口服生物可利用的NMT抑制剂靶向血液和实体癌症。Zelenirstat是新型NMT抑制剂的主要药物，使Pacylex能够将NMT用作癌症治疗的新临床靶点。

Pacylex is conducting a multi-center Phase 1/2a study in Canada in patients with R/R NHL and advanced solid tumors. The IND for a Phase 1 multiple ascending dose study in acute myeloid leukemia (AML) has been cleared and the FDA has granted zelenirstat both Orphan Drug Designation and Fast Track Designation for AML.

Pacylex正在加拿大对R/R NHL和晚期实体瘤患者进行多中心1/2a期研究。急性髓性白血病（AML）1期多次递增剂量研究的IND已被批准，FDA已授予zelenirstat孤儿药名称和AML快速通道名称。

The US Department of Defense is supporting the initial clinical investigation of zelenirstat in patients with AML. The Cure Cancer Foundation supported initial clinical studies through its World's Longest Games. .

美国国防部正在支持zelenirstat在AML患者中的初步临床研究。治愈癌症基金会通过其世界上最长的游戏支持初步临床研究。 .

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, such as statements relating to future events or the Company's future financial and operating performance, as well as the Company's business plans, growth initiatives, and objectives and prospects.

本新闻稿包含适用证券法含义内的前瞻性声明和前瞻性信息，例如与未来事件或公司未来财务和经营业绩相关的声明，以及公司的经营计划，成长计划和目标和前景。

Generally, forward-looking statements and forward-looking information may be identified by the use of forward-looking terminology, including the words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'goal,' 'expect,' 'strategy,' 'future,' 'likely,' 'proposed,' 'scheduled,' 'forecast,' 'budget,' 'could,' 'would,' variations of such words of phrases and other similar expressions, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved.

一般来说，前瞻性陈述和前瞻性信息可以通过使用前瞻性术语来确定，包括“相信”，“可能”，“将会”，“估计”，“继续”，“预期”，“意图”，“应该”，“计划”，“目标”，“期望”，“策略”，“未来”，“可能”，“提议”，“计划”，“预测”，“预算”，“可能”，“将会，“这些短语和其他类似表达式的变体，或通过使用表明某些行为，事件或结果可能，可能，将会或可能发生或实现的单词或短语。

However, the absence of these words does not mean that a statement is not forward looking. Forward-looking statements and forward-looking information are subject to numerous factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the Company's ability to successfully execute on its business plans and strategies, avoid delays in planned clinical trials, hire and retain key personnel, obtain appropriate or necessary governmental approvals to market potential products and obtain future funding for product development and working capital on commercially reasonable terms, changes in laws, and  general macroeconomic conditions, including economic slowdowns, recessionary risks, rising inflation and interest rates, and supply chain disruptions.

但是，缺少这些词语并不意味着声明不是前瞻性的。前瞻性声明和前瞻性信息受多种因素，风险和不确定性的影响，可能导致实际结果出现重大差异，包括但不限于公司成功执行其业务计划和战略的能力，避免计划中的延误临床试验，雇用和留住关键人员，获得适当或必要的政府批准，以销售潜在产品，并在商业合理的条件下获得未来的产品开发和营运资金，法律变化和一般宏观经济条件，包括经济放缓，隐性风险，通货膨胀和利率上升以及供应链中断。

Forward-looking statements and forward-looking information are based on the beliefs of managemen.

前瞻性声明和前瞻性信息基于管理者的信念。

Contacts:

联络：

Michael Weickert Ph.D

Michael Weickert博士。

650-218-1840

650-218-1840

michael.weickert@pacylex.com

michael.weickert@pacylex.com

Source: Pacylex

来源：Pacylex

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189481

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/189481